Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype

Share this content:
Despite promising prior data on nintedanib, the addition of the drug to a standard regimen did not improve survival in patients with a specific type of lung cancer.
Despite promising prior data on nintedanib, the addition of the drug to a standard regimen did not improve survival in patients with a specific type of lung cancer.
The following article features coverage from the International Association for the Study of Lung Cancer (IASLC) 2018 meeting. Click here to read more of Cancer Therapy Advisor's conference coverage.

In a surprising reversal from what was seen in a phase 2 study on nintedanib, results from the phase 3 LUME-Meso trial, released during the IASLC's 19th World Conference on Lung Cancer, demonstrated that nintedanib had no survival benefit when combined with pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma (MPM) with epithelioid histology.

The phase 3 trial protocol was created with the results from phase 2 in mind, in which patients with this specific form of lung cancer received nintedanib in addition to a pemetrexed/cisplatin regimen. In that trial, the addition of nintedanib improved progression-free survival in patients within this subgroup.

The current study evaluated 458 systemic chemotherapy-naive patients with the epithelioid subtype of MPM who were randomly assigned to receive combination therapy (500 mg/m2 pemetrexed and 75 mg/m2 cisplatin) on day 1 and either 200 mg bid nintedanib or matched placebo on day 2.

There were no statistically significant nor clinically meaningful improvements in either overall survival or progression-free survival across the nintedanib arm.

“Unfortunately, the phase 3 results of LUME-Meso did not confirm that nintedanib in combination with pemetrexed/cisplatin prolongs patients' lives … However, the trial reaffirms the need for solid confirmatory studies that are adequately sized, to challenge the standard of care in advanced malignant mesothelioma,” concluded the study's lead researcher, Giorgio Scagliotti, MD, PhD, the University of Turin, Italy, in an official meeting press release.

Read more of Cancer Therapy Advisor's coverage of the IASLC 2018 meeting by visiting the conference page.

Reference

  1. International Association for the Study of Lung Cancer. LUME-Meso study shows nintedanib plus pemetrexed/cisplatin does not improve progression-free or overall survival in patients with malignant pleural mesothelioma of epithelioid subtype [press release]. Published September 25, 2018. Accessed September 25, 2018.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs